Details for Patent: 7,341,744
Summary for Patent: 7,341,744
| Title: | Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer |
| Abstract: | Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition. |
| Inventor(s): | Edward James Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan, David F. Sesin |
| Assignee: | Napo Pharmaceuticals Inc |
| Application Number: | US09/712,033 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
| Patent landscape, scope, and claims: | Scope and Claim Analysis of US Patent 7,341,744: Oral Enteric-Controlled Proanthocyanidin Polymer for Secretory Diarrhea US Patent 7,341,744 is a U.S. method-of-treatment patent built around one active substance class (aqueous soluble proanthocyanidin polymer isolated from Croton spp. or Calophyllum spp.), one clinical target (secretory diarrhea), one administration route (oral), and one key formulation architecture (stomach protection via controlled release and/or enteric coating, including enteric-coated beads). The claim set is broad on species and patient population and narrower on the formulation type and coating chemistry. It is not a “composition of matter” claim in the excerpt you provided. It is a method claim with defined dosing ranges, defined active source, and defined stomach-protection formulation requirements. That structure drives freedom-to-operate risk: oral dosing that uses the Croton/Calophyllum proanthocyanidin polymer and provides stomach protection can fall within the independent claim even if other excipients, tablet vs capsule selection, or patient subtypes vary, depending on which dependent limitations are met. What does US 7,341,744 claim cover for secretory diarrhea treatment?Short answer: The patent claims oral treatment of secretory diarrhea in humans and selected animals using an aqueous soluble proanthocyanidin polymer isolated from Croton spp. or Calophyllum spp., dosed at 0.1 to 100 mg/kg/day, with the polymer formulated to protect it from stomach conditions via controlled release and/or enteric coating, in a pharmaceutically acceptable carrier. Independent claim 1: what must be practicedClaim 1 requires all of the following elements to be met:
Claim 1 is therefore a functional formulation requirement (“protect from the stomach environment” in controlled release), not a single fixed polymer coating material, and it does not confine the dosage form to tablets or capsules in the independent claim. Independent claim 18 and claim 37: what changesClaim 18 changes the formulation requirement to a more explicit architecture:
Claim 37 again broadens patient and animal set but uses language like claim 1: the polymer is formulated to protect from the acidic conditions of the stomach in a controlled release preparation. Practical consequence: the independent claims create two overlapping infringement paths:
Which specific active-source limitations matter most for scope?Croton vs CalophyllumThe claims cover polymers isolated from either:
The dependent claim 2 and claim 19 narrow Croton to Croton lechleri. Scope impact: A provider using proanthocyanidin polymers from non-Croton/non-Calophyllum sources can avoid the claims if the active is not within “isolated from a Croton species or Calophyllum species.” Likewise, using non-proanthocyanidin polymers, or proanthocyanidin oligomers rather than the claimed “aqueous soluble proanthocyanidin polymer composition,” creates avoidance leverage. “Aqueous soluble proanthocyanidin polymer composition”This is an identity constraint that can be used in litigation to dispute whether an accused product’s active material meets the definition. It is also central to claim construction:
Scope impact: even if a product contains proanthocyanidins, it may be outside the claims if its active is not the claimed “aqueous soluble proanthocyanidin polymer composition,” or not “isolated from” the claimed plant species. What are the dose and indication boundaries in US 7,341,744?Dose window: 0.1 to 100 mg/kg/dayAll independent method claims require dosing in the 0.1 to 100 mg/kg/day window. Dependent claim 16 and claim 35 restrict further to 0.1 to 40 mg/kg/day. Scope impact: If an accused product uses dosing outside 0.1 to 100 mg/kg/day, it avoids the independent claim. If it is within 0.1–100 but outside 0.1–40, it may still infringe independent claims but not those dependents. Indication: secretory diarrheaDependent claim 8 specifies bacterium-caused secretory diarrhea; claim 9 specifies non-infectious etiology; claim 10 lists non-infectious subtypes:
Claims 12 and 30 cover:
Claim 13 and 31 cover:
Scope impact: The claims are framed as method-of-treatment of secretory diarrhea. If an accused use targets a different diarrhea mechanism (osmotic, inflammatory non-secretory, functional diarrhea not fitting “secretory”), it can argue non-infringement on the “secretory diarrhea” limitation. What formulation requirements drive infringement risk: controlled release vs enteric coating?Independent claim 1 and 37: controlled release to protect from stomach environment/acidClaim 1 requires a controlled release formulation protecting the polymer from the stomach environment. Claim 37 adds “acidic conditions of the stomach.” Claim 1 does not require:
So claim 1 reads on many oral stomach-protecting approaches so long as the polymer is “protected” from stomach conditions in a controlled release preparation. Independent claim 18: explicit enteric-coated polymerClaim 18 requires the polymer to be coated with an enteric coating. This typically increases proof burden for an accused infringer (presence of an enteric-coated active or particles), but it is also a clearer infringement theory than “controlled release” alone. Enteric coating chemistry in dependent claim 20Dependent claim 20 specifies:
Scope impact: claim 20 only applies to products whose enteric coating is that copolymer. Products using other enteric coating materials could avoid claim 20 while still potentially infringing claim 18 if they meet the enteric-coating requirement broadly. Dosage forms: tablets and enteric-coated capsulesDependent claim 3 and claim 21 cover compressed tablets. Dependent claim 6 and claim 24 cover:
Scope impact: The independent claims do not require beads or a capsule. However, the beads architecture can be used to map infringement across particle-based enteric delivery designs. Lubricant limitation: magnesium stearateDependent claim 4/22 restrict tablet formulations to those with magnesium stearate. Scope impact: This is narrow. It likely matters only for tablet designs and only if an infringer’s lubricant/excipient package omits magnesium stearate. Animal feed administration: claim 15 and claim 34Claim 15 and claim 34 allow the animal administration route:
Scope impact: This materially broadens infringement scenarios into veterinary and livestock product manufacturing, including mixing/providing the composition in feed. How broad is the claim set versus common competitive design-arounds?Main infringement “tripwires”A product is at high risk if it checks these boxes simultaneously:
Likely carve-outs
Claim-by-claim scope map (what each dependent claim adds)Claims 2, 19 (Croton lechleri)
Claims 3, 21 (compressed tablet)
Claims 4, 22 (lubricant required)
Claims 5, 23 (magnesium stearate)
Claims 6, 24 (enteric-coated capsule)
Claims 7, 25 (beads in capsule)
Claims 8, 26 (bacterial etiology)
Claims 9, 27 (non-infectious etiology)
Claims 10, 28 (non-infectious subtypes)
Claims 11, 29 (infant/child)
Claims 12, 30 (HIV-associated chronic diarrhea)
Claims 13, 31 (cholera diarrhea)
Claims 14, 32, 33 (animal treatment and animal set)
Claims 15, 34 (animal feed)
Claims 16, 35 (0.1 to 40 mg/kg/day)
Claims 17, 36 (carrier)
Claim 18 (enteric coating on active/polymers)
Claim 20 (enteric coating chemistry)
What is the practical infringement theory: method performance vs product supply?US 7,341,744 is drafted as method of treatment. That typically raises infringement questions around:
Because the independent claims require a specific dose and stomach-protection formulation, infringement in practice hinges on whether the end-user (prescriber/manufacturer under instructions) administers the accused oral controlled-release/enteric product at the specified mg/kg/day range for secretory diarrhea. How do these claims compare with common patent landscape patterns in GI antidiarrheals?Method claims like this often coexist with:
In US 7,341,744, the claim architecture pushes coverage toward:
This is narrower than a broad “use of proanthocyanidin polymers for diarrhea” patent because it anchors to source species, aqueous soluble polymer identity, and stomach-protection formulation function. What exclusivity and generic entry risks flow from a method-of-treatment patent?Key point: Even if a generic or biosimilar is approved for an active ingredient, a method-of-treatment patent can still block or constrain market entry if:
For challenge pathways:
Because the claims also include dependent disease-context limitations (HIV-associated chronic diarrhea, cholera), a label that is limited to other diarrhea subtypes could reduce infringement exposure relative to a broad secretory diarrhea indication, but the independent claim can still be asserted if the proposed product is used to treat secretory diarrhea generally. Which claim features should be prioritized for freedom-to-operate mapping?
Key Takeaways
FAQs1) Does US 7,341,744 require an enteric coating to infringe? 2) If an accused product uses Croton lechleri, does it automatically infringe? 3) Can a product avoid the patent by changing tablet excipients like magnesium stearate? 4) How does animal feed administration affect infringement exposure? 5) Do claims targeting HIV-associated chronic diarrhea or cholera provide additional independent coverage? References
More… ↓ |
Drugs Protected by US Patent 7,341,744
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,341,744
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 430477 | ⤷ Start Trial | |||
| Australia | 2030302 | ⤷ Start Trial | |||
| Australia | 4988197 | ⤷ Start Trial | |||
| Australia | 775330 | ⤷ Start Trial | |||
| Canada | 2269078 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
